Hypermutation is observed only in antibody H chain V region transgenes that have recombined with endogenous immunoglobulin H DNA: implications for the location of cis-acting elements required for somatic mutation by unknown
Hypermutation Is Observed Only in Antibody H 
Chain V  Region Transgenes  That Have Recombined 
with Endogenous Immunoglobulin H  DNA: 
Implications for the Location of c/s-acting Elements 
Required for Somatic Mutation 
By Angela M. Giusti and Tim Manser 
From the Department of Microbiology and Immunology, Jefferson Cancer Institute, Thomas 
Jefferson Medical College, Philadelphia, Pennsylvania 19107 
Summary 
Mice with transgenes containing an antibody H  chain V region (V.DJ.) gene were used in an 
analysis of the c/s-acting elements required for hypermutation of immunoglobulin (Ig) V genes. 
These transgenes can somatically recombine with endogenous IgH DNA, leading to the formation 
of functional heavy (H) chains partially encoded by the transgenic VsDJ.. The transgenomes 
in the five different lines of mice analyzed  contain as little as 150 bp, and as much as 2.8 kb 
of natural DNA flanking the 5' side of the V. and either 1.5 or 2.3 kb (including the intronic 
enhancer and 5' matrix attachment region [MAR]) flanking the 3' side of Vs. Hybridomas were 
constructed from immunized transgenic mice, and transgenes present in these hybridomas that 
had or had not recombined to form functional H chain loci were sequenced. The data obtained 
show that: (a) the recombined transgenes contain hypermutated V. genes; and (b) among such 
transgenes, even those containing only 150 bp of natural V. 5' flanking sequence and several 
kilobases of 5' plasmid vector sequence display a frequency, distribution, and type of mutation 
characteristic  of conventional IgH loci. The data also indicate that transgenic VsDJ. genes that 
have not recombined with endogenous IgH DNA are not substrates  for hypermutation, even 
if they are flanked by 2.8 kb of natural 5' DNA, and 2.3 kb of natural 3' DNA, including the 
J.2-JH4 region, a MAR, and the intronic enhancer. Collectively, the data suggest that sequences 
5' of the V. promoter are dispensable,  a V. promoter and the intronic IgH enhancer region 
are not sufficient,  and a region(s) within or 3' of the IgH constant region locus is requisite, 
for hypermutafion of Ig V. transgenes. 
ntibody V region diversity in mice and humans is gener- 
ated by the combinatorial joining of germline V gene 
segments that are members of heterogeneous multigene fam- 
ilies, the deletion and de novo addition of nucleotides at the 
junctions of these V segments during  joining, and hypermu- 
tation of the resulting V genes (1). While characterization 
of the cis- and trans-acting factors involved in the rearrange- 
ment of V gene segments and the generation of junctional 
sequences has proceeded rapidly in recent years (2, 3), the 
mechanism of hypermutation continues to remain enigmatic. 
Current evidence suggests that hypermutation is induced 
during an immune response (4-6), introduces mainly single- 
nucleotide replacements at a rate estimated to be 10 .3 per 
base pair per cell division (7), acts efficiently only in and im- 
mediately around fully rearranged V genes (8-14), and is not 
causally linked to isotype switching (15, 16). Since V gene 
hypermutation plays a central role in the affinity maturation 
of antibodies (6,  17, 18), and is intimately associated with 
the development of B cell memory (17, 19-23), the complete 
elucidation of its mechanism, as well as how this mechanism 
is regulated, is of central importance to an understanding of 
the development of antibody specificity and humoral im- 
munity. 
While direct approaches to the characterization of the trans- 
acting factors involved in the hypermutation process continue 
to remain elusive, transgenic mouse technology has allowed 
investigations of necessary c/s-acting elements. Two groups 
have demonstrated that the V genes in Ig transgenes encoding 
functional ir L chains are mutable (24,  25),  demonstrating 
that  the cis-acting  elements requisite for mutation of V~ 
genes must lie in reasonably  close proximity (24,  26).  In- 
deed, the recent work of Sharpe et al.  (25) has implicated 
a requirement for the downstream g enhancer in the muta- 
tion process. 
During the course of the immune response of strain A/J 
mice to the hapten p-azophenylarsonate (Ars), 1 antibody V 
regions encoded by a single combination of V region gene 
I Abbreviations used in this  paper: Ars, p-azophenylarsonate; MAR, matrix 
attachment  region. 
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Volume 177  March  1993  797-809 segments become predominant (20). We term such V regions 
"canonical" The distribution and type of somatic mutations 
in the canonical V regions expressed by hybridomas isolated 
during  the anti-Ars  response are well characterized,  as are 
the effects of recurrently observed mutations on the affinity 
of such V regions for Ars (18). We found that in mice bearing 
transgenomes comprised of a canonical V. gene and various 
amounts of natural 5' and 3' flanking DNA, the transgenic 
V. and associated 5' flanking region could recombine with 
endogenous IgH DNA, leading to the expression of trans- 
genic Va-encoded antibody (27).  Sequence analysis  of the 
transgenes present in hybridomas derived via Ars immuniza- 
tion of these transgenic mice has allowed us to evaluate the 
influence of proximal 5' and 3' flanking regions, and whether 
the V. gene is part  of a functional  H  chain locus,  on V. 
hypermutation. 
Materials  and Methods 
Transgenic Mice.  The construction  and characterization of the 
transgenic mice used in this study have been described previously 
(27). Briefly, plasmids containing  an unmutated canonical V.DJ. 
gene  cloned  from  the  36-65  anti-Ars hybridoma,  and  various 
amounts of natural 5' and 3' flanking sequence, were used to con- 
struct  the mice. The following lines, containing  the amount of 
V. 5' and 3' flanking DNA and transgene copy numbers indicated, 
were used in this study: X1 and X7 lines, 150 bp of 5' flank and 
1.5 kb of 3' flank, five to seven and two to three copies, respec- 
tively; PR15 and PR19 lines, 2.8 kb of 5' flank and 2.3 kb of 3' 
flank, 8-10 and 5-6 copies respectively; and XR14, 150 bp of 5' 
flank and 2.3 kb of 3' flank, three to four copies. The founder mice 
were derived from matings of (A/J  x  C57BL/6)F1 female mice 
to A/J male mice, and the mice used in this study were obtained 
by backcrossing these founders to A/J mice. 
Immunization and Generation of Hybridomas.  Transgenic mice 
were given an intraperitoneal injection of 100/~g Ars-KLH in CFA. 
I wk later, the mice received three intraperitoneal injections of 50 
#g Ars-KLH in PBS at 3-d intervals. 3 d after the final injection, 
the mice were killed and their  spleens used in fusions to Sp2/O 
as previously described (15). Hybridoma supernatants were screened 
for reactivity with an anticanonical V region mAb, E4, and the 
isotype of antibodies expressed by positive clones was determined 
by ELISA, all as described previously (15). 
eDNA and Genomic PCR Amplifications.  Total  ILNA was pre- 
pared from hybridoma cells by a guanidinium isothiocyanate-CsC1 
procedure described previously (28, 29). The V. RNA was con- 
verted to cDNA using  a 3' primer  complimentary  to sequences 
within the first 60 nudeotides of the appropriate C.1 exon and 
amplified using a 5' primer homologous to sequences in the leader 
exon of the 36-65 variable region. 1-5/~g of total RNA was sub- 
jected to reverse transcriptase (RT)-PCIL essentially as described 
(30) using a thermocycler (model 60; Coy Laboratory Products Inc., 
Ann Arbor, MI). Each of the primers contained restriction  sites 
(XhoI in the case of constant region primers and Sad for V. leader 
region  primers  [VhL])  to  facilitate the  subsequent  cloning  of 
the  amplification  products  into  the  pBluescript  KS(-)  vector 
(Stratagene, La Jolla,  CA). 
Canonical V. genes in genomic DNA were amplified with V. 
leader and J.2 primers  (both containing  restriction  sites) for 35 
cycles at 94~  for 1 min,  55~  for 2 min,  and 72~  for 3 min. 
The products  were digested with the appropriate restriction  en- 
zymes and cloned into the polylinker of pBluescript KS(-). 
Nucleotide Sequencing.  Direct sequencing of Ig RNA was per- 
formed as described previously (4). pBluescript plasmid DNA was 
sequenced with 3sS-dATP using the Sequenase Version II kit (U.S. 
Biochemicals Corp., Cleveland, OH) with oligonucleotide primers 
as described by the manufacturer. Some of the sequences were also 
obtained using the "Taq DyeDeoxy" kit (Applied Biosystems, Inc., 
Foster City, CA), and the automated sequencer (Applied Biosystems, 
Inc.),  or  the  "fmole"  PClk  sequencing  kit  (Promega  Biotec, 
Madison, WI). 
RNA Analysis.  Northern blot analyses were performed with 
formaldehyde agarose gels using standard procedures. RNase pro- 
tection assays were conducted as described (31). Antisense RNA 
was synthesized  from a 486-bp StuI-MscI restriction fragment cloned 
behind the T3 promoter in pBluescript KS(- ). This fragment was 
obtained from the genomic V. clone of the 36-65 hybridoma and 
encompasses from V. codon 41 to 186 bp 3' of the end of J.2. An 
RNA transcription kit (Stratagene, La JoUa, CA) and o~-[32P]UTP 
were used to synthesize the antisense probe from plasmid linear- 
ized with Sad. After hybridization and RNase digestion, protected 
fragments  were analyzed on a 6% polyacrylamide/urea gel and 
visualized by autoradiography. 
Results 
Experimental Strategy.  Clues to the location of the c/s-acting 
elements  requisite  for V.  hypermutation  are  provided by 
previous findings  that:  (a)  mutations  are  observed at high 
frequency only within a region encompassing the rearranged 
V. gene and '~300 bp 5' of the V coding region and  1 kb 
3' of the coding J segment, irrespective of which J segment 
is used (8, 11, 12); and (b) hypermutation appears mechanisti- 
cally unrelated to H chain class switching since mutation can 
take place in a single IgH locus both before and after switching 
mediated by DNA deletion to a variety of different C region 
genes (15, 16). These results suggested that a rearranged V. 
gene and only limited amounts of 5' and 3' flanking DNA 
might contain all the cis-acting elements required for full ac- 
tivity of the hypermutation  process. 
We have constructed mice bearing multicopy transgenomes 
containing  an  unmutated  canonical  V.DJ.  gene,  various 
amounts of natural 5' and 3' flanking sequence, and plasmid 
vector sequences. We previously demonstrated that in such 
mice a transgenic V.DJ. gene, along with 5' flanking Ig and 
plasmid sequences, could become juxtaposed next to IgH C 
region genes in B cells, leading to the production of anti-Ars 
antibodies partially encoded by the transgenic V. (27). Hy- 
bridomas expressing canonical V regions that are isolated from 
Ars-KLH-immunized transgenic mice often contain a "hy- 
brid" transgene-IgH locus that encodes their functional H 
chains,  and always contain other copies of the original trans- 
gene. The configuration of the transgenes present in our var- 
ious transgenic  hybridomas is diagrammed  in Fig.  1. 
The transgenic V. gene and 5' flanking DNA present in 
the X1, X7, and XR14 lines of mice somatically recombines 
with endogenous IgH DNA to give rise to an expressed H 
chain locus containing  150 bp of 5' transgenic Ig DNA fol- 
lowed by plasmid DNA. In two X7 hybrid loci we have charac- 
terized in detail, the plasmid DNA is ",~2.2 kb in length and 
is flanked on the 5' side by at least 1.1 kb of DNA that bears 
798  Hypermutation  of V. Transgenes Transgenic Arrays 
X1,X7  lib  II ~lIII  II =~ ....... 
lines  .......  -  "N 
PR15, PR19  I  IIng  ~  I  IIH  g 
lines  -"  " 
XR14  ling  g  =  =I~II=I~IIH  g  ~ 
line  "  " "  w  "  w  "N ....... 
Expressed Heavy Chain Loci 
Hy~id in Xl  and  =====~a  I  I  n  ~  ~  .....  =111  .... 
x7 lines 
Hyt~id in XR14 line  ~1|1  B  0  ~  .....  illl  .... 
HytxidinPR15  ~  nil  n  A  .....  ==n  .... 
and PR19 lines  v 
Conventional  I  i  O  ~  4~  .....  ilia 
locus 
_  -~ ...... 
,aF  -N 
pBluescdpt DNA  ￿9  Enhancer (MAR)  ==iim  Non-Transgenic DNA 
II  LVDJH2 Coding Exons  --  -'=,'Switch" Region DNA  .....  Uncharacterized DNA 
U  Unrearranged JR3+4 Segments  IUI  ? Constant Region Exons  ~  Ig DNA 
Figure  1.  Schematic diagram of the structure  of 
transgenomes, transgene-IgH hybrid loci, and conven- 
tional H  chain loci. Two copies of each repeat unit 
of each type of transgenic array are shown; (N) the 
unit repeat. Each transgenic hybridoma has either a 
hybrid or conventional expressed H chain locus con- 
taining a canonical V.  gene,  as well as additional 
copies of the original transgene that remain present 
as tandem repeats. The length of plasmid sequences 
present in most hybrid loci are as yet undefined (jagged 
edge), but always appear to be flanked by sequences 
not derived from transgenic DNA (thick lines). Our 
data indicate in all hybrid loci only one transgenic V. 
copy has been juxtaposed next to endogenous  IgH 
DNA (see text). 
no homology to transgenic or Ig DNA. The transgenic V. 
gene and 5' flanking DNA present in the PK15  and PR19 
lines somatically recombines with IgH DNA giving rise to 
an expressed locus with several kilobases of natural 5' Ig DNA, 
followed by plasmid sequences. In both types of hybrid loci, 
regions 3' of the transgenic V. appear identical to those ob- 
served in conventional IgH loci that encode IgG H  chains. 
That is, the unrearranged J.3 and J.4 segments are present, 
followed by the matrix attachment region (MAK)/enhancer 
region, followed by a region containing switch DNA, and 
then the C~ exons (27;  and A. M.  Giusti and T. Manser, 
unpublished results).  Canonical V.-expressing hybridomas 
isolated from all of the lines of transgenic mice contain one 
of these types of hybrid loci or a conventional endogenous 
IgH locus, in addition to copies of the transgene that have 
not recombined with IgH DNA. Conventional and pulsed 
field gel electrophoresis combined with Southern blotting 
analysis strongly suggests that only one transgene V. copy 
is associated with IgH DNA in the hybrid loci expressed in 
all of our hybridomas. Moreover, fluorescence in situ hybrid- 
ization analysis of metaphase chromosomes from normal B 
cells and hybridomas obtained from the X1, XR14, PR15, 
and PR19 lines indicates that the majority of transgene copies 
are present in their germline chromosomal location in cell 
lines containing a hybrid locus. In all cases this germline lo- 
cation is not syntenic with the IgH locus (A. M. Giusti and 
T. Manser,  manuscript in preparation). 
Since many of the hybridomas contain a copy of a canon- 
ical VaDJ. transgene that has recombined with IgH DNA, 
and copies that have not, sequencing of such transgenes should 
provide insight into IgH elements not included in the trans- 
genes that may be necessary for V. hypermutation. Further, 
since the transgenes in different lines of mice contain varying 
amounts of natural 5' and 3' sequence flanking the V.DJ., 
such an analysis would also allow an evaluation  of the re- 
quirements for proximal V. 5' and 3' flanking regions in the 
hypermutation process. 
Sequencing of V. Genes Expressed by Ars-induced Transgenic 
Hybridomas,  The origin and isotypic class of antibodies ex- 
pressed by the canonical V region-expressing transgenic hy- 
bridomas used in our sequencing analyses are shown in Table 
1. The V. regions of H  chain RNA expressed by these hy- 
bridomas were sequenced,  either directly using RT and an 
appropriate C region primer, or by PCR amplification of V. 
region eDNA followed by doning and sequencing of the PCR 
product. The data in Fig. 2 show that the V. genes contain 
numerous somatic mutations and many contain transgene- 
Table  1.  Origins  and Characteristics  of mAbs Generated  from 
Ars-KLH-immunizecl  Transgenic Mice 




X7 (female)  NX7 (female) 
NX20 (female) 
X1 (male)  NX41  (female) 
PR15 (male)  NPR.11 (male) 
NPR14  (male) 
PR19 (female) NPR18  (female) 
XR14 (male) NXR6 (female) 
NXR26 (female) 
X7-5D3  Gl,r 
X7-4G7  GI,K 
X7-3D12  G2b,r 
X7-3C5  Gl,r 
X20-4  G1,K 
X41-1  G2b,K 
X41-2  G2b,g 
PRll-4  GI,K 
PK14-3  Gl,r 
PR18-1  G2b,r 
XR6-1  G3,K 
XR26-3  G1,K 
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CANON  ATG  GGA  TGG  AGC  TTC  ATC  TTT  CTC  TTC  CTC  CTG  TCA  GTA  ACT  C,  CA  (]GT b~fC  CAC  TCT  GAG  GTT  CAG  C'FF  CAG  CAG  TCT  GGA 
36-65(7G)  ..................................................................... 
X7 -5D3  ....................................................................  T- 
X7-3C5  ...................................  T ..................................  C  ...... 
X7 -3D12  ....................................................................... 
X41-1  .................................................................  T ....... 
X41-2  ....................................................................... 
PRII  4  ............................................................  A-- 
PRI4 -3  ............................................................. 
PRIS-I  .............................................  C-  --C  ................ 
i0  20  -30 ....  CDRI  ...... 
CANON  GAG  ~  GTG  AGG  GCT  GGG  TCC  TCA  GTG  AAG  AT<]  TCC  TGC  AAG  C~T  TCT  OGA  TAT  ACA  ~  ACA  AGC  TAC  GGT  ATA  AAC  TGG  GTG 
36-65  (TG) ..................................................................... 
XT-SD3  --  -A  ......  A .............................................................. 
X7-3C5  ...................................................  A-  A .............. 
XT-4G7  ........................  A ............... 
X7-3DI2  ........................................................  A .............. 
X41-1  ................................  C  .................  C ........ G  ......... 
X41-2  .....................................................  G  ......... 
XR6-1  .......................................... 
XR26  -3  ......................  T  ................... 
PRII-4  ..........  A ....................................................... 
PRI4 -3  .......................................................  C ............... 
PRIS-I  .................................................................... 
40  -50 .......................  CDR2  .....  60 .................... 
CANON  AAA  CAG  AGG  OUT  GGA  CAG  GGC  CTG  GAA  TGG  A~f  GGA  TAT  ATF  AAT  CCT  (]GA  AAT  G~T  TAT  ACT  AAG  TAC  AAT  GAG  AAG  TIC  AAG 
36-65  (T~3] ........................................................................ 
XT-SD3  .................................  C  ........ G  ...... T-  C-C  ---  -{3  ............. 
X7-3C5  .............................................  A .....  T-  C-C  ................ 
X7 -4G7  ....................................................  TC  -T  .......  C ......... 
X7-3DI2  ................................................  C  .......  T-  -C  ................. 
X20-4  .................................  G  C  ............  A  ..... A  ...........  A  ..... 
X41-1  ......................................................  T  ................ 
X41-2  ........................................................  T-  GC .............. 
XR6 -  1  .....................................................  T  -  -C  ............. 
XR26-3  ....................................................  T .................... 
PRII-4  .......................................................  A  G ........... 
PRI4-3  ......................  G  .............................  T ................... 
PRIS-I  ...................................................  T .................. 
.......  70  80  90 
CANON  GGC  AAG  ACC  ACA  CTG  ACT  GTA  GAC  AAA  TCC  TCC  AGC  ACA  GCC  TAC  AT<;  CAG  ~  AGA  AGC  CTG  ACA  TCT  GAG  GAC  TCT  C-CA GTC 












PRI8  i 
-A ...................................................................... 
.................................................................... 
.............  C ...............................  G ......................... 
.........  T  ....................................................  C ........ 
.....................................  T  ................................. 
...........................  G ..................  G .......................... 
..............................................  G  ...................... 
....................................  A ............................  G  ...... 
.......................................................................... 
..............  C  ........................................................ 
---  G  ............  -G  ................................................. 
................  C ........................................................ 
98 
CANON  TAT  TFC  TGT  GCA  AGA  T(IN 
36-65(9]3)  ............  G 
X7-SD3  ---  C .............  G 
X7 -3C5  ....  T  ........  G 
X7-4G7  ..........  G ....  G 
XT-3DI2  ...........  G 
X20-4  ..............  C 
X41-1  ......  T .... G 
X41  2  C ..........  G 
X]96-1  .............  G 
XR26-3  ................  G 
PRII-4  ...............  T 
PRI4 -3  ..............  G 
pRIS-I  ...............  G 
D  dlt2 
TAC  TAT  GGT  GGT  AGC  TAC  Nh~  TTT  GAC  TAC  q~G  GGC  CAA  GGC  ACC  ACT  CI~  ACA  GTC  TCC  TCA 
GTC  .............  T  -  -  TAC  ................................. 
GTC  ..............  T  -  -  TAC  ...........  C ....................... 
GTC  ...........  T  ---  TAC  .................................. 
GTC  ..........  T  --  TAC  ...... 
GTC  .............  T  ---  TAC  ......  A ........ G ......  T ................ 
GAG  .............  T  ---  AAC  ...................................... 
GTC  ..........  T  --  TAC  ......  C ................................ 
GTC  ............  T  --  TAC  ....................................... 
GTC  ............  T  ---  TAC  ........................................ 
GTC  ............  T  -  T  q'lT  ......  G .............................. 
C~CF  ..........  T  - -  ~  ......................... 
GTC  ............  T  --  TAC  .......................... 
GTC  ...........  T  ---  TAC  ........................ 
Figure  2.  Sequences  in  the V. 
coding  region  of V.  mKNA  ex- 
pressed by transgenic  hybridomas. 
The sequences  are compared  with 
the consensus sequence of unmutated 
canonical V. genes (CANON) and 
the unmutated sequence of the 36-65 
transgene  V.  gene  [36-65(TG)]. 
Sequence identity is indicated by a 
dash,  differences  are  shown  ex- 
plicitly. The position of the mature 
amino-terminal codon is indicated 
(I), as are the location of CDRs and 
regions encoded by D  and J.2 gene 
segments. 
type junctional nucleotides.  Previous Southern blotting anal- 
yses have shown that in the hybridomas expressing V. genes 
with transgene-type junctional nudeotides, these V. genes 
are present in transgene-IgH  hybrid loci (Fig. 1). In contrast, 
such analyses have shown that the canonical  V. genes con- 
taining other types  of junctional nucleotides reside in con- 
ventional, endogenous IgH loci (27, and A. M. Giusti and 
T. Manser, unpublished results).  The distribution and type 
of somatic mutations in canonical V, genes present in both 
conventional and hybrid loci indicate that antigen selection 
acted on the products of these genes. A large fraction of the 
mutations  cause  amino  acid  substitutions,  mutations  are 
present at a higher frequency in CDKs than in other regions 
of the genes, and mutations are recurrently observed that cause 
amino acid substitutions previously  shown (18) to result in 
increases in affinity for Ars (e.g., ACT to ATT at codon 58). 
Overall,  the frequency, distribution, and type of mutations 
observed  in canonical  V.  genes present  either  in conven- 
tional or hybrid loci are similar. 
Transgene-IgH  Hybrid Loci Containing Small Amounts of  Nat- 
ural 5' Flanking DNA Are Hypermutated.  We previously ob- 
tained  PCR clones of the V,DJ.  and immediate flanking 
regions present in the hybrid loci of the hybridomas X7-5D3 
and X7-3C5,  and k phage clones of the hybrid loci in the 
hybridomas X7-3D12 and X7-4G7 (27). These four cell lines 
were isolated from a single Ars-KLH-immunized transgenic 
mouse of the X7 line.  The nucleotide sequences of V.DJ. 
and flanking regions of these dones are shown in Fig. 3. The 
sequences within the V. coding region of the clones agree 
with those obtained from RNA (Fig. 2), revealing many mu- 
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the V. coding regions in these hybrid loci.  Some of these 
mutations observed in the 3C5 and 5D3 clones might have 
resulted from ~q polymerase errors. However, the frequency 
of Taq errors we observe in control experiments conducted 
under the conditions used to amplify the X7-5D3 and X7- 
3C5 hybrid loci is never >0.1% (E. Ingersoll and T. Manser, 
unpublished observations). Since the frequency of mutation 
in the clones is >1% (in both coding and much of the non- 
coding regions),  the majority of the observed nucleotide 
changes are probably not due to ~q errors.  Moreover,  the 
distribution of mutations in flanking regions in the PCR clones 
is nonrandom (see below), and several of the mutations are 
shared with the phage clones. 
In toto, the transgene-IgH hybrid loci reveal a frequency, 
distribution, and type of mutation that is characteristic  of 
conventional Ig loci (8-14).  The frequency of mutation in 
the 5' transgene-derived plasmid sequences is 0%, in the re- 
gion from the promoter to the 3' end of the leader intron 
it is 0.4%, in the VH coding region it is 2.0%, in the J,2- 
JH3 3' flanking DNA it is 1.8%,  in the Ja3-J.4  region it is 
0.7%,  and  in  the DNA  3'  of J.4  it  is  0%.  Such a  "3' 
skewing" of the distribution of mutation relative to the V 
coding region appears to be a trademark of the somatic mu- 
tation process (11, 13, 14). The mutations are mainly nucleo- 
tide replacements, nucleotide transitions are predominant, and 
several mutations in noncoding regions are shared among the 
clones, indicating a common mutational genealogy. Again, 
these attributes are all characteristic  of somatically mutated 
natural Ig loci (32-34). 
Transgenic VH Genes Present in IgH Hybrid Loci Are Hyper- 
mutated, but Other Transgenic V, Genes Are Not.  All of our 
hybridomas  contain  an  expressed  canonical  V.  gene  as- 
sociated with IgH C region DNA (either due to transgene 
rearrangement or conventional VDJ rearrangement), as well 
as other copies of the transgene present on different chromo- 
somes than the IgH locus. We therefore could evaluate the 
action of hypermutation that had occurred in a single B cell 
clone on an expressed conventional or hybrid locus V. gene 
and on transgenic V, genes that are not part of functional 
H  chain loci. PCR primer combinations that would allow 
amplification of all canonical V,DJ, genes were used in reac- 
tions containing hybridoma genomic DNA, and the resulting 
PCR products were cloned and sequenced.  To control for 
possible ~q polymerase errors,  each hybridoma DNA was 
subjected to two independent amplifications  and clonings. 
Sequences  of canonical V. clones derived from hybrid- 
omas X7-5D3 (X7 line) and X41-1(X1  line) are shown in 
Figs. 4 and 5 as compared with the 36-65 transgene [36-65 
(TG)]  and the sequences derived from H  chain RNA (Fig. 
2)  expressed  by  these hybridomas (M).  Most  cloned V. 
genes are members of one of two classes; those that contain 
only occasional, unique base changes at a frequency expected 
for Taq polymerase error, and those that agree nearly entirely 
with the corresponding somatically mutated H chain RNA 
sequence. The frequency of V. clones that are members of 
the former class correlates with the estimated copy number 
of the transgenes in the hybridomas. These data suggest that 
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only the canonical V. gene that is part of the transgene-IgH 
hybrid locus has undergone hypermutation. This conclusion 
is strongest in the case of X7-SD3, since the transgenic copy 
number in the-K7 line is two to three, and the 16 PCR clones 
we have analyzed  makes it highly likely that all canonical 
V, genes would have been sampled. 
Since the X1 and X7 lines contain the least amount of nat- 
ural 5' (150 bp) and Y (1.5 kbp; no enhancer or MAR) flanking 
sequence of all of the lines we constructed, their transgenes 
could be lacking a c/s-acting element(s) necessary for hyper- 
mutation that is present in the transgenes containing more 
extensive flanking DNA. To test this idea, the canonical V. 
genes present in genomic DNA of hybridomas PRll-4 (PR15 
line), PR14-3 (PR15 line), and PR18-1 (PR19 line) were PCR 
amplified, cloned, and sequenced as described above. The mice 
from which these hybridomas were derived all contain V. 
transgenes with 2.8 kb of 5' DNA, and 2.3 kb of 3' DNA 
(including the intronic enhancer and 5' MAR) in 5-10 copies. 
The PRll-4 hybridoma contains a conventional IgH locus 
that encodes a canonical H chain. Fig. 6 shows that no genomic 
PCR clone sequences were obtained that agree with the mu- 
tated RNA sequences. Since the transgene copy numbers in 
the PR lines of mice are high, and the PCR primers used 
will amplify any canonical V. gene, this is not an unex- 
pected result. However, only 1 of the 17 genomic sequences 
contained a mutation, a frequency easily accounted for by 
Taq polymerase error. 
Transc@tion of  the Transgenomes.  Analysis of the transcrip- 
tional activity of the transgenomes is complicated by the fact 
that while functional VH promoters and sometimes intronic 
enhancers  are present, natural 3' splice acceptor and tran- 
scription termination/polyadenylation sites are not. Thus, 
transcripts that may be initiated from the V, promoter in 
unrearranged transgenes would be expected to be of hetero- 
geneous length, and would lack a 3' poly(A) tail. Such tran- 
scripts  would most probably be extremely unstable. 
Nevertheless,  since  the transcriptional activity of a  V. 
gene may influence its susceptibility to hypermutation, we 
performed Northern blot and RNase protection analysis on 
total tLNA isolated  from the spleens of X1, PR15, PR19, 
and XR14 lines of transgenic mice.  Using a vector probe, 
diffuse signal in the low molecular weight range of the gels 
was obtained from these RNAs in Northern analysis (data 
not shown). In the RNase protection studies, R.NA probes 
derived from the VDJ region and immediate 3' flanking DNA 
of the transgene were used. Probe fragments were protected 
by some of the splenic RNAs of sizes (243 bp) indicative 
of the presence of spliced transcripts derived from the trans- 
genomes (Fig. 7, see legend for details). Since transgene-IgH 
hybrid loci can not be detected in splenic DNA of unim- 
munized transgenic mice (27; and A. M. Giusti and T. Manser, 
unpublished results),  these transcripts are most probably de- 
rived from unrearranged transgenes.  The small amount of 
243-bp fragment protected by transgenic spleen as compared 
with 36-65 (the transgene donor) RNA, taken together with 
the  data  obtained  from  Northern  blots,  suggests  that 
transgenome-derived transcripts are very unstable. X7  -TG  ~AGCTCACrCATTAG~ACCccAGGCTTfAC-ACT1~FA~Tg1TGTGTGC*%AyrG~IGAGCGGATAACAATFDD~CACAGGAAACAC.CTA~ 
X7-4G7H  ..................................................................................................  X  ........... 
X7-3DI2H  ..................................................................................................  X ........... 
XT-~  CCATC,  A~AOGt'~AA~TPAA~CTAAAGGGAA~  GGTCGACC4YFATCGAT~TATCGAA~AG 
X7  -4G7H  .............................................................................................................. 
)(7  -3DI2H  .......................................................................................................... 
X7-T~  CCC~ ~AGTTCFAGA  TGGG~AGG  TC  CTTAACTAAAAAATGCAC~  ATG  AATATC~TC  AC  CC  ~  A~  AGT~TA~  A~  C  AC  AC 
X7-5D3H  ...................................................................................................... 
X7  -3C5H  ...............................................  G ............................................................ 
X7  -4GTH  ..................................................................................................  G ....... 
X7-3DI2H  ..................................................................................................  G ...... 
-19 
X7-TG  CC~AAAACAACC?ATGA'I~C  ACACTCCCq~ACACACI~ACTCAAACC  ATG  GGA  TGG  AGC  "C?C  ATC  ~  CTC  qq~C  CTC  CTG  TCA  GTA 
X7-SD3H  ........................................................................................... 
X7  -3C5H  ............................................................................................. 
X7  -4G7H  ..........................................  A ............................................... 
X7  -3DI2H  ............................................................................................... 
1 
X7-TG  ACT  GCA  G/GTAAGGGGGTCAccAq~AAATCTGAAGAAGCAAAATGG~L-"~GGATGTCACI~ACATCCA~qq~L~L~q~t~;CAG/GT  GTC  CAC  TCT  GAG 
X7  -SD3H  .............................................................................  C .................... 
X7  -3C5H  T .........................................................................  C ..................... 
X7-4G7H  ............................................................................................. 
X7  -3DI2H  ........................................................................................ 
i0  20 
X7-q~  GTT  CAG  CIwF  CAG  CAG  TCT  C93A  GCT  GAG  CTG  ~  AGG  GCT  GGG  TCC  TCA  GTG  AAG  ATG  TCC  TGC  AAG  GCT  TCT  GGA  TAT  ACA  q*IC 
XT-5D3H  ......................  T .....  A  .......  A .......................................... 
X7-3CSH  .................  C  ......................................................... 
X7-4G7H  ...........................  A  .................................................... 
X7  -3DI2H  ................................................................................... 
-30  ..... C~9RI  ......  40  -50  ....................  C13R2 
XT-TG  ACA  AC-C  TAC  GGT  ATA  AAC  TGG  GTG  AAA  CAG  AGG  CCT  G(2A  CAG  G(3C  CTG  GAA  TGG  ATr  GGA  TAT  Aq'P  AAT  CCT  G(2A  AAT  GGT  TAT 
X7-SD3H  ...............................................................  C .........  G  ..... 
X7-3C5H  ....  A-  A  .....................................................................  A .... 
X7-4G7H  ......  A  ....................................................................... 
X7-3DI2H  ......  A  ....................................................................  C  ...... 
.........  60  ............................  70  80 
X7-TG  ACT  AAG  TAC  AAT  GAG  AAG  qTFC  AAG  GGC  AAG  ACC  ACA  CTG  ACT  GTA  GAC  AAA  TCC  TCC  AGC  ACA  GCC  TAC  ATG  CAG  CTC  AGA  AGC 
X7-SD3H  -T-  C-C  ---  ~G  ...........  A ...................................................... 
X7-3CSH  -T-  C-C  ........................................................................ 
X7-4G7H  -TC  --T  .......  C ............................  C ..................................  G  - 
X7-3DI2H  -T-  --C  ..........................  T  ....................................... 
90  98  D 
X7-TG  CYG  ACA  TCT  GAG  GAC  ~  GCA  GTC  TAT  TTC  TGT  GCA  AC.A  TCG  GTC  TAC  TAT  C.GT  GGT  AGT  TAC  TAC  ~  GAC  TAC  TGG  C~C  CAA 
X7-5D3H  ...........................  C  ............  -G GTC  .............  T  --~  TAC  .............  C  .... 
X7-3C5H  .......................  T  ..........  -G GTC  ............  T  --~  TAC  ............. 
X7~4G7H  ............................  G--  --G  GTC  ...........  T  -  -  TAC  ................ 
X7-3DI2H  .............  C ..........  X  .............  -(3 GTC  ...........  T  ---  TAC  ....  A  ....  X  --  -G 
JH2 
X7-TG  GGC  ACC  ACT  CTC  ACA  GTC  TCC  TCA  GGTGAGTCCq~2AAAACCI~ATTCA~AGATAGAq~ACTUzC~AAATGTGTGTATC 
X7-SD3H  .................................................  G .............  C ........  C ....  G ................ 
X7  ~3C5H  ...........................  G ........................  A  .................................  C-  -- 
X7  -4G7H  ..............................  C  ........................  C  C ............................. 
X7~3D[2H  ......  T  ..........  X  ...........................  X-X ....................................... 
X7-TG  TGAAq'FYCAGGTCAT(]AAGGACTAGGGACACCTIL.'C-GAGTCAGAAAGGGTCA~~ACC,  C  AGACAGACATCCTCAGCTCCCAGACCTCATC~CAGAGA 
X7-SD3H  ................  C ........................  G ..................................................... 
X7  -3C5H  ..............................................................................  C  ............ 
X7  -4G7H  .......................................................  X  ..................  X  ................ 
X7-3DI2H  .........  X .....  G ..................................  X ..... X  ........................................ 
X7-TG  q'I'I~ATAGAGATCCTGGCCAGCA~GCTAGTCCCIL'q~TTCTA~CYC  A~CIL'~ATCTGAGATAATCCTGGAGCCL~TAC.CCAAGGATCA~Iq~TA 
X7  -5D3H  ..................................  C-C--C  ............................  T  .......................... 
X7  -3C5H  ........................................................................................... 
X7-4G7H  ......................................  C ................................  A .......  A  ............. 
X7-3DI2H  ................................................................................................... 
JH3 
X7-TG  TTGTCAG~AATCAqffGTTGTCACAATG~f<~CCI'GGTTTGCTTA~CAAGGC.A~TC~qV'TCq~3CA6~  GTGAGTCCTAA~CATTCFAAATC~ 
X7-5D3H  ......................................  T ............................................................... 
X7-3CSH  .........................................  T ......................  A ..........................  C  .... 
X7-4G7H  ........................................................................................... 
X7  -3DI2H  .......................................................................................... 
Figure  3.  Sequences of the VH 
genes and 5' and 3' flanking regions 
present in transgene-IgH hybrid loci 
cloned  from  Ars-KLH-induced 
transgenic hybridomas derived from 
the X7 line of mice. Sequences are 
shown as described in Fig.  2,  in 
comparison  with the sequence of the 
plasmid used to construct  the X7 
line (X7.TG). pBluescript vector se- 
quence is double underlined, and the 
J. gene segments are single under- 
lined.  The  3'  XbaI  site  used  in 
cloning the  5D3  and  3C5  PCR 
products is shown in bold type. Se- 
quence was obtained at least 1 kb 
3' of this site in the 4G7 and 3D12 
phage clones, and, when compared 
with the sequence of 36-65 DNA 
in this region, revealed no evidence 
of somatic mutations.  Ambiguous 
nucleotides  are indicated (X). 
Discussion 
The B cell hypermutation process appears to act on canon- 
ical VH  transgene-IgH  hybrid loci containing  only  small 
amounts of natural 5' flanking DNA in a manner indistin- 
guishable from conventional Ig loci. This conclusion is based 
on the premise that most of the mutations observed in such 
hybrid loci took place after recombination of the transgenes 
with endogenous IgH DNA. Collectively, our data strongly 
suggest that this was the case. The formation of transgene- 
IgH hybrid loci occurs at a very low frequency (such loci 
can not be detected in unimmunized  mice, and only can be 
detected via PCR or hybridoma technology in Am-immunized 
mice),  and it is unlikely that four independent recombina- 
tion events took place in the B cell population of mouse NX7, 
giving rise to the hybrid loci in hybridomas X7-3C5,  X7- 
3D12, X7-4G7, and X7-SD3, and their many unique muta- 
tions.  These  hybrid loci contain shared somatic mutations 
in noncoding regions, suggesting derivation from a common 
recombined and mutated "precursor hybrid locus?' Some of 
the V. genes present in hybrid loci that we have sequenced 
do not contain mutations (data not shown), indicating that 
the mechanism that results in transgene-IgH recombination 
is not responsible for the high frequency of mutation we have 
observed. Finally, all of the transgenes that are not part of 
hybrid loci that we have analyzed contain base changes at 
a frequency not greater than that expected from PCR error. 
The  150 bp of natural 5' DNA flanking V. coding se- 
802  Hypermutation  of V. Transgenes X7-TG  C  ATG  ~Aq~GC  CFI~AC~ACC  AAG  ATIL-~L~fG  CAAAC(]GGAATCAAGA  CAAA~CA  .  A~ 
X7  -5D3H  ...................................................................................  A ........................... 
X7  -3C5H  ..................................................  G ..................  A  ....................................... 
XT-4G7H  .............................................................................................................. 
X7-3DI2H  ......................................................................  X ....................................... 
XT-TG  C~TGATATTAGAACTGAAGTATGAq~3AAGGATCIGCX2AGAA  AGGCAGAATCFI~  A~ATCGG ACTCTIG TG  AG 
X7  -5D3H  .....................................................................  g .................................... 
X7-3C5H  ........................................................................................................ 
X7-4G7H  ---G  .................................................................................................. 
X7-3DI2H  ........................................................................................................ 
XT-TG  AATFAGGGGC  TG  AC  AGTTG AT(]G  ~[G  AC  AAT]TCAGGGTCAGTGACTG  ~  AATAT  CTAAAG A(](]CX]TC  CAGGGG 
X7-SD3H  .............................................................................................................. 
XT-3C5H  --  -T  .............................................................................................  A 
xT-4G7H  .......................................................................................................... 
XT-3DI2H  ................................................................................................... 
X7  -TG  ~  AC  AGGCAGGG AACAGAA~3 TOG  AACAATGACITGAAqX]Gq~GATIL~/~I~GACACCAGGAATTfX]CATAAq~TCCf~AGTT(;C  CC~A~PCTAGT 
X7  -SD3H  ...............................................................................  C ......................  G-  -- 
X7  -4G7H  ............................................................................................................ 
X7  -3DI2H  ........................................................................................................ 
JH4 
X7  -TG  CAGA~'I"~TI'I~TATAGAGGAAAAATCCACTATI~3TG  ATTACTATGCTAT~GACTA  .GTCAC  CGTCTCCTCAGGTAAGAATG 
X7-5D3H  ....  G ......................................  C .................................................................. 
X7  -4G7H  .............................................................................................................. 
X7-3DI2H  ............................................................................................................. 
X7-TG  GC~~A'I'IT  1"  rAACCq'FI~TFATGGAG~AACATI~]CAGACTAAqL~VI~GATA~CCT~AGGGAACC~AAATT(]GGAAATAAAC 
x7-SD3H  ............................................................................................................ 
X7  -4GTH  ...............................................................................  XXXX ......................... 
X7  -3DI2H  ............................................................................................................. 
X7-TG  TG  TCTAGGGATCTC  AG  ~C  CT]IPAGGACAG  ATTATCq~ CACA~CTAAGAATCTGTG--IG  AT(]GTG  TIDGTGG ~  ~  ~  A~ AT  ~A~ 
X7  -5D3H  ............................................................................................................ 
X7  -4G7H  ...............................................................  X ............................................. 
X7  -3DI2H  ........................................................................................................... 
X7  -TG  AGGCICAq'ITGAGGAAGATC~TAAAAC  AATCCTAT(]GCTG  AAGGG  ATAG~~qrlvI~CAG.1.1  -  r  1  -  1AGAATAAAAGTAqT~  ATATACTr 
X7  -SD3H  .............................................................................................................. 
X7  -4G7H  .............................................................................................................. 
X7  -3DI2H  .............................................................................................................. 
X7  -TG  CA(]GACCA~TGACAGCATTTATACAGTATCCGA~aCATAGGGACAAAG  ~AGATIq~-~3AGGAATGTI~CGCAC"FAGATTGTTFAA 
X7-5D3H  ............................................................................................................. 
X7-4G7H  ........................................................................................................... 
X7-3DI2H  .......................................................................................................... 
xbaX 
X7-TG  AAC  t  TC  A~AAGGAGAGCq~  q~AGTGATIIGAGTCAAGGAAG  AAA(]GCATCT  AGqrFC<ZfG  TC TAGA 
X7-5D3H  ......................................................................................... 
X7-4G7H  ........................................................................................ 
X7  -3DI2H  ..............  X  ..............................  X ........................................ 
quences in X1 and X7 hybrid loci contain only the purine- 
rich block of nucleotides, the "heptamer:' octamer, and TATA 
box (all known to be important for efficient promoter func- 
tion; reference  35), and the RNA cap site. Analysis of)~ phage 
clones containing X7 hybrid loci has shown that ~2.2 kb 
of pBluescript vector DNA is present immediately 5' of the 
promoter region, and no other Ig locus or transgene DNA 
is present within 1.1 kb 5' of this vector DNA (see Fig. 1). 
Thus, sequences immediately 5' of the V. promoter can be 
replaced by unrelated sequences without noticeable effect on 
the mutation process, indicating that c/s-acting  elements neces- 
sary for hypermutability do not exist 5' of the promoter. There- 
fore, our data do not support models for the somatic muta- 
tion  process  that  propose  that  5'  cis-acting  elements  are 
important (36), but leave open the possibility that a func- 
tional  V. promoter is requisite for mutation. 
It is somewhat more difficult to interpret the low frequency 
of mutation, entirely accountable by PCR errors, in the trans- 
genes that have not recombined with endogenous IgH DNA. 
Explanations based on absence  of the tram-acting factors neces- 
sary  for  hypermutation are  unlikely since  the  V.  genes 
within a transgene-IgH hybrid or conventional  IgH locus 
that were present in the same B cell clone are observed to 
be mutated. However, our current ignorance of the nature 
of the hypermutation process limits  further conclusions. 
Whether mutation occurs "processively"  such that several 
nudeotide changes are introduced nearly simultaneously in 
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a single V gene, or in a stepwise "distributive"  fashion over 
the course of many cell divisions, is a current subject of con- 
troversy (6, 7, 37-40).  If the former case were true, the lack 
of a high frequency of mutation in all of our V, transgenes 
that have not recombined with endogenous IgH DNA could 
not be easily interpreted as evidence that these transgenes lack 
the c/s-acting elements necessary for hypermutability.  In this 
case, the stringent action of antigenic selection, which could 
operate only on loci encoding functional H  chains, would 
further complicate matters. If"processive" mutational events 
took place infrequently, the only such events that would be 
represented among antigen-induced  hybridomas  would be 
those that resulted in an antibody with increased affinity for 
antigen, i.e., those that took place in the functioning V. 
gene. For such a scenario to account for the data, the number 
of mutations introduced per "processive" event would have 
to be large. For example, in the case of the X7-SD3 and X41-1 
hybridomas (Figs. 4 and 5), 13 and 9 mutations, respectively, 
occurred in the hybrid locus V.s, while few or no mutations 
took place in the many other V.s present in unrearranged 
transgene  copies. 
In contrast, a number of previous observations support a 
"distributive"  model for hypermutation. In hybridomas ex- 
pressing hypermutated V genes, V. and VL genes are usu- 
ally observed to be mutated to similar extents,  even when 
only translationally  silent mutations are considered (6,  15, 




X7 -5D3 -5 
X7  5D3-9 
X7-5D3  -i0 
X7-SD3-11 
XT-SD3  12 
X7-SD3-13 
X7 -5D3  14 




X?-5D3  -19 
X? -5D3-20 
X? -5D3  21 
36-65  (TG) 
X7-SD3-M 
X7-SD3-1 
X7-5D3  -2 
X7 -5D3 -5 
X7-5D3-9 
-6  1 
ACT  GCA  G/GTAAGGGGGTCACCAT]'FCTAAATCTGAAGAAGCAAAATGGC~ATGTCACTCACATCCAC~~AG/GT  GTC  CAC  TCT  GAG 
....................................................................................... 
..........................................................................  ~  ........................ 
........................................................................................ 
........................................................  C ................... 
........................................................................... 
.............................................................................. 
..........................................................  C .................. 
.......................................................................... 
..............................................  C .................. 
............................................................................ 
................................................................  C ................... 
...........................................................  C ..................... 
.......................................................................... 
........................................................................... 
...................................................  C  ................ 
..................................................................... 
i0  20 
GTT  CAG  CTT  CAG  CAG  TCT  GGA  GCT  GAG  CTG  GTG  AGG  C-CT GGG  TCC  TCA  GTG  A~3  AT(]  TCC  TGC  AAG  O~CT TCT  GGA  TAT  ACA  TTC 
..............  T ....  A  .....  A ............................ 
..............................................  C  ............ 
...................  T-  --  A .....  A ........................................ 
...................................................... 
..................................................... 
X7-5D3-10  ..........  A  ............................................. 
XT-SD3-11  .................................................... 
XT-SD3-12  .................  T ....  A .....  A ................................. 
X7-SD3-13  ......  A  .................................................. 
X7-SD3  -14  .................  T ....  A ....  A ........................ 
X7-5D3-15  ................................................. 
XT-5D3  -16  ...............  T-  --  A .....  A .......................... 
XT-5D3  -17  .............  T-  --  A ......  A .............................. 
X7-SD3-18  ........................................................  C 
X7-5D3  -19  ................................................. 
X7 -5D3-20  ................  T  ....  A  --  -  A ......................... 
X7 -5D3 -21  ..................................................... 
-30 ..... CDRI  .....  40  -50  ................  CDR2 
36-65(TG)  ACA  AGC  TAC  GGT  ATA  AAC  TOG  GTG  AAA  CAG  AGG  CCT  GGA  CAG  GGC  CTG  GAA  TOG  ATT  GGA  TAT  Aq'P  AAT  CCT  GGA  AAT  GGT  TAT 
X7-SD3-M  ......................................  C ........  G  .... 
X7-5D3  -i  ...................................................... 
X7-qO3-2  ....................................................  ~ ......... Q  ..... 
X7-5D3  -5  .............................................................. 
X7-5D3-9  ......................................  C  ..... G  --  - 
X7-SD3-10  ....................  A  ........................ 
X7-SD3-11  ............................................. 
X7  5D3-12  ....................................  C .....  G  .... 
X7-5D3-13  ................  A  ................................. 
X7-SD3-14  ...................................  C .......  G  -- 
X7-5D3  -15  ............................................. 
X7-SD3  -16  ........................................  C .....  G  .... 
X7 -5D3 -17  ...................................  C .....  G  ..... 
X7-5D3-18  ............................................... 
X7-SD3-19  ................................................ 
X7-SD3-20  ......................................  C  .......  G  --- 
XT-SD3-21  ................................................ 
.......  60  ..................  70  80 
36-65(TG}  ACT  AAG  TAC  AAT  GAG  AAG  TIC  AAG  GGC  AAG  ACC  ACA  CTG  ACT  GTA  GAC  AAA  TCC  TCC  AGC  ACA  GCC  TAC  ATG  CAG  CTC  AGA  AGC 
X7-SD3  M  -T  C-C  --  G ........  A ...................................... 
X7-SD3  i  .............................  T  ......................... 
~7-5D3-2  -T-  C-C  --  -G  ..........  A .................................................... 
X7-SD3-5  .................  G  ................................... 
X7-5D3-9  T-  C  C  -  -G  ........  A ......................................... 
X7-SD3-  i0  ................................................ 
X7-SD3-11  ................................  C ............. 
XT-SD3-12  -T-  C-C  -  -G  .........  A ................................. 
X7  5D3  13  .................................................. 
X7-SD3  14  T  C  C  --  -G  ........  A ........................................ 
X7-SD3  -15  ................................................. 
X7-SD3  -16  T  C-C  --  G ..........  A  ...................................... 
X7-5D3-17  -T  C-C  -  -G  ......  A  .................................... 
X7-SD3-18  ................................................... 
X7  5D3  19  .................................................. 
￿  -T  C-C  --  G .......  A ...................................... 
X7-SD3  21  ............................................... 
90  98  D  JH2 
36-65(TG)  CTG  ACA  TC?  GAG  GAC  TCT  GCA  GTC  TAT  TIC  TGT  GCA  AGA  TC~  h[NN TAC  TAT  C4~T GGT  AGC  TAC  ~  TIT  GAC  TAC  TGG  OGC  CAA 
XT-SD3  M  ......................  C ...........  G  GTC  ...........  T  ---  TAC  ...........  C-  -  - 
X7-5D3-1  ...............................  G  GTC  ...........  T  ---  TAC  .............. 
X7-SD3-2  .......................  ~ ...........  O  GTC  ..............  T  ---  TAC  ...........  ~ .... 
X7-5D3-5  ..................................  G  GTC  .............  T  ---  TAC  ..........  C .... 
X7-SD3-9  ..................................  G  GTC  ............  T  --  TAC  ............. 
X7-5D3-  i0  ............................  G  GTC  ........  T  TAC  .........  C .... 
X7-5D3-11  ................  C ...........  G  GTC  ..........  T  -  TAC  ...........  C .... 
X7-5D3-12  ................  C  ........  G  GTC  .......  T  ---  TAC  ........  C-  -  - 
X7-5D3-13  ..................................  G  GTC  ..........  T  -  TAC  ..........  C-  -- 
X7-SD3-14  ..............  C ........  G  GTC  ............  T  ---  TAC  ...........  C-  -- 
X7-SD3-15  .............................  G  GTC  ............  T  -  TAC  ............ 
X7-SD3-16  .................  C .........  G  GTC  .........  T  --  TAC  ...........  C  --- 
X7-5D3-17  .....................  C ..........  G  GTC  .........  T  --  TAC  .........  C  --- 
X7-SD3-18  .............................  G  GTC  ............  T  ---  TAC  ............. 
X7-SD3-19  .................................  G  GTC  .............  T  --  TAC  ............... 
X7-5D3-20  ...................  C ...........  G  GTC  ...........  T  --  TAC  .............  C-  -- 
X7-5D3-21  ...............................  G  GTC  ...........  T  ---  TAC  ........... 
Figure  4.  Sequences  of the V, 
PCR done inserts obtained from the 
X7-5D3 hybridoma. Sequences are 
shown as in Figs. 2 and 3, as com- 
pared  with  the  sequence  of  the 
36-65  transgene and the sequence 
of the H chain mRNA expressed by 
X7-5D3 (X7-5D3-M). Sequence of 
clones derived from the two inde- 
pendent amplifications and donings 
are separated by a solid  line.  The 
clone insert present in X7-5D3-9 ap- 
pears to have resulted from artifac- 
tual exchange of DNA between un- 
mutated  and  mutated  V.  loci 
during PCR since this insert lacks 
the cluster of mutations centered at 
codon  11.  The recurrent  G  to  C 
change in the J.2 region  of the se- 
quences may also represent a PCR 
artifact of this type, since this mu- 
tation does not always cosegregate 
among the clones  with mutations 
present in the rest of the RNA se- 
quence. 
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36-65(TG)ACT  C,  CA  G/GT~CCATI'IL'TAAATC'I~AAC,  AAGCAAAATGGCCTGGGAq~'I~CAC'I~ACATCC  ~AG/GT  GTC  CAC  TCT  GAG 
X41-124  ...... 
X41-3  ...... 
X41-4  ...... 
X41-5  ..... 
X41-6  ...... 
X41-7  ...... 
X4]-12  ...... 
X41-13  ...... 
X41-14  ..... 
X41-15  ..... 
X41-.t~  ...... 
x41-21  ...... 
x41-28  .... 
X41-29  ..... 
X41-30  .... 
X41-31  .... 
X41-32  ..... 
36-65(~)OTT  CAG  ~  CAG  CAG  TCT  GGA  GCT  GAG  ~  GTG  AGO  ~  OGG  TCC  TCA  GTG  AAG  ATG  TCC  TGC  AAG  GCT  TCT  GGA  TAT  ACA  TTC 
X41-194  .........................................................  C  ........... 
X41-3  ................................................................ 















36-65(qIg)ACA  AGC  TAC  GGT  ATA  AAC  q~G  GTG  AAA  CA(]  AGG  CC~  (]CA  CAG  GGC  CTG  GAA  TGG  ATT  GGA  TAT  AT] ~ AAT  CCT  GGA  AAT  GGT  TAT 
X41  -M  ....  C .........  G  .............................................................. 
X41-3 
X41  4 
X4l  5 
X41-6 












36-65(~)ACT  AAG  TAC  AAT  GAG  AAG  ~  AAG  GGC  AAG  ACC  ACA  ~  ACT  GTA  GAC  AAA  TCC  TCC  AGC  ACA  GCC  TAC  AT(3  CAG  CTC  AGA  AGC 
X41-1M  -T ...................................................  G ...................  G ........ 
...........................  T  ............................................................ 
I0  20 











..............................................................  C  ............. 
............................................................................ 
.......................................................................... 
..............................................................  C  ........... 
-30 .....  CDRI .......  40  -50 .......................  CDR2 
....  C ......  -G  ................................................................. 
...........................................  r  ....................................... 
.....  C  .......  -G  ................................................................. 
.....  C  .......................................................................... 
.....  C  ......  -G  ................................................................... 
.........  60 ............................  70  B0 
X41-3  ..................................................................................... 
X41-4  -T ....................................................  G ...................  G ........ 
X41-5  .................................................................................... 
X41-6  .................................................................................... 
X41-7  ....................................................  G ...................  G ........ 
X41-12  ............................................................................... 
X4]-13  ................................................................................. 
X41-14  ................................................................................... 
X41-15  ............................................................................... 
X41-16  .................................................................................... 
X41-21  -T ....................................................  G .......................... 
X41-28  .................................................................................. 
X41-29  -T ...................................................  G ....................  G ....... 
X41-30  ................................................................................. 
X41-31  ................................................................................... 
X41-32  ................................................................................. 
90  98 
36-65(T~])CTG  ACA  qL'T  GAG  GAC  TCT  GCA  GTC  TAT  T~C  TGT  GCA  AGA  TC~  NNN 

















D  JR2 
TAC  TAT  GGT  GGT  AGC  TAC  ~  TIT  GAC  TAC  TOG  GC-C  CAA 
.................................  T ....... G  GTC  ..............  T---  TAC  .............  C .... 
........................................  ~3  GTC  ..............  T  ---  TAC  .................. 
.................................  T ......  -G  GqC  ..............  T  ---  TAC  .............  C .... 
........................................  -G  GTC  ..............  T  ---  TAC  .................. 
.........................................  -G  GTC  .............  T  ---  TAC  .................. 
................................  T ......  -G  GTC  ..............  T  ---  TAC  .............  C .... 
........................................  -G  GTC  ..............  T  ---  TAC  .................. 
.........................................  -G  GTC  ..............  T  ---  TAC  .................. 
.........................................  G  GTC  ..............  T  ---  TAC  .................. 
........................................  -G  GTC  ..............  T  ---  TAC  .................. 
........................................  -G  GTC  ..............  T  ---  TAC  .................. 
........................................  -G  GTC  ..............  T  ---  TAC  .................. 
.........................................  G  GTC  ..............  T  ---  TAC  .................. 
.................................  T .......  G  GTC  ..............  T  ---  TAC  .............  C .... 
........................................  -G  GTC  ..............  T  ---  TAC  .................. 
........................................  -G  GTC  ..............  T  ---  TAC  .................. 
........................................  -(3  GTC  ..............  T  ---  TAC  .................. 
Hgure 5.  Sequences of the PCR 
clone  inserts  obtained  from  the 
transgenic  hybridoma  X41-1.  Se- 
quences are shown as described in 
Fig. 4. Clone inserts X41-4 and 29 
share all of the mutations present 
in the H chain RNA. Clones X41-7 
and 21  share mutations  with the 
mRNA  only  in  discrete  V. 
subregions  and  appear  to  have 
resulted from artifactual exchange 
of DNA between mutated and un- 
mutated canonical V. loci during 
PCB.. 
805  Giusti  and Manser 1 
36-65(q13)  T~ZTAAATCTGAAGAAOCAAAATC(~CCR2GGATGTCAC]R~ACA"/~~/GT  GTC  CAC  TCT  GAG  GTT  CAG  CI~  CA~  CAG  q~T 
PRI  4 -  3-M  ......................... 
PRI4 -3-3  .......................................................................................... 
PRI4 -3  ~4  ............................................................................................. 
PRI4 -3  -5  .................................................................................. 
PRI4-3-10  .......................................................................................... 
PRI4-3-11  ................................................................................................. 
PRI8-1  -M  ..............  C-  --C  .......... 
~18-i-i  ................................................................................. 
PRIS-I-9  .................................................................................... 
PRIS-I-10  .............................................................................................. 
PRIS-I-II  ............................................................................................... 
PRI1-4  -M  .............................. 
PRII-4-1  ................................................................................ 
PRII-4-2  ...........................................................................  =  .......... 
PRII-4-3  ..................................................................................... 
PRII-4  -4  .................................................................................. 
PRII-4-5  .................................................................................. 
PRI1-4  -6  .................................................................................... 
PRII-4-7  .............................................................................. 
PRII-4-8  ............................................................................... 
PRI1-4  -9  .................................................................................... 
I0  20  -30 .....  CDRI ..... 
36-65(~G)  ~A  G~T  GAG  CTG  GTG  AGG  GCT  GGG  TCC  TCA  ~  AAG  AT  TCC  TGC  AAG  GOT  TCT  GGA  TAT  ACA  TTC  ACA  AGC  TAC  (~T  ATA  AAC 
PRI  4 - 3-M  ............................................................  C ........ 
PR14-3-3  ................................................................. 
PRI4 -3-4  ................................................................ 
~14-3  -5  ................................................................ 
PRI4-3-10  ........................................................................... 
~,14-~-~i  ...................................................................... 
PRI8-I-M  ................................................................ 
PRIS-I-I  .................................  A ............................ 
PRIS-I-9  ..................................................................... 
~18-I-10  ......................................................................... 
pR18-1-11  ...................................................................... 
PRI1-4-M  ---  A .............  A  ......................................................... 
PRII-4  -i  .............................................................. 
~11-4-2  ....................................................... 
PRII-4-3  ..................................................................... 
PRII-4-4  ............................................................... 
PRI1-4  -5  .............................................................. 
PRII-4-6  .......................................................... 
PRII-4-7  ........................................................................... 
PRII-4-8  ............................................................... 
PRII-4-9  ................................................... 
40  -50 ...................  CDK2  .....  60  ......... 
36-65(TG)  TGG  GTG  AAA  CAG  AGG  CCT  GGA  CAG  GGC  CTG  GAA  TGG  AT?  GGA  TAT  AT?  AAT  CCT  043A AAT  OGT  TAT  ACT  AAG  TAC  AAT  GAG  AAG 
PRI4-3-M  ..............................  G  ..................  T  ........... 
PRI4 -3  -3  ........................................................ 
PR14-3-4  ........................................................ 
PRI4 -3  -5  ........................................................ 
PRI4-3  -i0  ............................................................... 
~4-~-iI  .................................................................. 
PRI8-I-M  .....................................................  T  .......... 
PRI8-1-1  ................................................................. 
PRIS-I-9  .................................................................... 
PRIS-I-10  ..................................................... 
PR18-I-II  ....................................................................... 
PRII-4-M  .................................................  A  G  - 
PRII-4  i  .................................................................. 
PRII-4  -2  ....................................................... 
PRII-4-3  .................................................. 
PRII-4  4  .............................................................. 
FRII-4-5  ................................................ 
~RII-4-6  ......................................................... 
PRII-4-7  .............................................................. 
~ii-4-8  ....................................................... 
PRII-4-9  ................................................... 
...........  70  80  90 
36-65{TG)  T]~  AAG  GGC  AAG  ACC  ACA  Cq~  ACT  GTA  GAC  AAA  TCC  TCC  AGC  ACA  GCC  TAC  ATG  CAG  CTC  AGA  AGC  CPG  ACA  TCT  GAG  GAC  TCT 
PRI4-3-M  .......  G .............  G  ....................................... 
PRI4 -3  -3  ............................................................ 
PRI4 -3  -4  ......................................................... 
PRI4-3  -5  ............................................................. 
FRI4-3-1O  ........................................................................ 
PRI4-3-11  ...................................................  ................... 
PRI8-1  -If  ...................  C .......................................... 
~18-i-i  .................................................... 
PRIS-I-9  .......................................................... 
PRIS-I-10  ...................................................... 
~R1fl-i-l]  .................................................................. 
PRI1-4  -M  ...................  C  ....................................... 
PRll-4-1  ...................................................... 
PRII-4  -2  ................................................................. 
PRII-4-3  ................................................................... 
PRI1-4  -4  ..................................................................... 
PRII-4-5  ................................................................. 
PRII-4-6  ............................................................. 
PRII-4  -8  ............................................................ 
PRII-4-9  ........................................................ 
98  D  JK2 
36-65(q~3)  C~A  GTC  TAT  TTC  TGT  GCA  AGA  TOG  GTC  TAC  TAT  GGT  GGT  AGT  TAC  TAC  T~T  GAC  TAC  TOG 
PRI4-3-M  ....................  G  ~  ........  T  --  TAC  ......... 
PR14-3-3  ..................  G  GTC  ............ T  --  TAC  ......... 
PRI4  3-4  .................  G  GTC  .......  T  --  TAC  ...... 
PR14-3-5  ................  G  GTC  ........  T  --  TAC  ..... 
PRI4-3-10  .....................  G  GTC  .............  T  -  -  TAC  ........... 
PRI4-~-]I  .....................  G  GTC  ..............  T  ---  T~%~  ......... 
PRI8-I-M  ...................  G  GTC  ..........  T  -  -  TAC  ............ 
PRIS-I-I  ....................  G  GTC  ........... T  ---  TAC  ..... 
PRIS-I-9  ..................  G  GTC  ..........  T  -  -  TAC  ............ 
PRI8-1-10  .....................  G  GTC  ..............  T  --  TAC  ....... 
PRIS-I-II  ......................  G  GTC  ..............  T  --  TAC  ........ 
PRII-4-M  ...................  T  CTT  .............  C  ---  GCC  ........ 
PRII-4  1  ..................  G  GTC  .............  T  ---  TAC  .......... 
PRII-4-2  .................  G  GTC  .........  T  -  TAC  ....... 
PRII-4-3  .....................  G  GTC  .............  T  ---  TAC  ........... 
PRII-4-4  ....................  G  GTC  ............ T  --  TAC  ...... 
PRII-4-5  ....................  G  GTC  ...........  T  ---  TAC  .......... 
PRII-4-6  .................  G  GTC  .......  T  -  TAC  ..... 
PRII-4  7  .................  G  ~  .........  T  --  TAC  .......... 
PRII-4-8  ....................  G  GTC  ..............  T  ---  TAC  ......... 
PRII-4-9  ................  G  GTC  .........  T  -  -  TAC  ........ 
Figure  6.  Sequences of the PCR clone in- 
serts obtained from the PR.14-3, PR18-1, and 
PRll-4 hybridomas. Sequences are shown as 
described in Fig. 4, except that sequences de- 
rived from the different hybridomas are sepa- 
rated by solid lines. 
806  Hypermutation of V. Transgenes Figure 7.  RNase protection analysis of total splenic RNA derived from 
transgenic mice. The analysis was performed as described in Materials and 
Methods. The schematic  diagram indicates  the sequences present in the 
probe: (diagonal  sloped boxes) pBluescript-derived sequences; (horizontal  sOiped 
box) natural  IgH sequence  flanking the VH region;  (stippled boxes) V~ 
coding sequence, Within coding sequence the D, J.2, and CDR.2 regions 
are indicated. The Vs-D and D-J. junctional residues  are indicated by 
black bars.  Some of the potential protected fragments of the probe are 
indicated: 426 bases would be protected by an unspliced transcript with 
junctional nudeotides complementary to the probe; 243 bases would be 
protected by a spliced transcript with junctional residues complementary 
to the probe; 174 bases would be protected by any transcript with V.-D 
junctional nucleotides that were not complementary to the probe. The 
lanes correspond to 5/*g of each total RNA, hybridized with identical 
amounts of probe, obtained from the indicated sources. Controls: lane 
A, undigested probe; lane B, 36-65 hybridoma; lane C, NX20-1 hybridoma 
(V.-D junctions  of functional H  chain  RNA  not  complementary to 
probe); lane D, NX41-1  hybridoma (junctional nucleotides of functional 
H chain KNA complementary to probe); lane E, spleen from a naive A/J 
mouse.  Experimentals: lane 1, B19-17 naive spleen (PK19 line);  lane 2, 
B15-4 naive spleen (PK15 line); lane 3, H15-35 naive spleen (PR15 line); 
lane 4, $2-2 naive spleen (PRH2 line, contains a transgene with extensive 
natural sequence flanking the 5' side of the 36-65 V. gene but no IgH 
enhancer [A. M. Giusti and T. Manser, unpublished results); lane 5, $1-24 
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ranged V genes present within the same B cell have been shown 
to have similar frequencies of mutation (11, 12). Finally, the 
sequences of hypermutated  V genes expressed by hybridomas 
derived from the same expanded B cell clone can often be 
related to one another via a multi-tiered mutational geneology, 
indicating that mutation was active in the clone over an ex- 
tended period(s) of cell division (7,  17, 32, 37, 38).  Given 
that hypermutation can take place in this fashion, i.e., mul- 
tiple times at multiple genomic sites during the growth of 
a B cell clone, our data indicate that the combination of a 
V. promoter (included in as much as 2.8 kb of natural 5' 
flanking DNA) and the intronic IgH enhancer is not sufl~dent, 
and a region 3' of this enhancer is requisite,  for hypermuta- 
bility of V. transgenes. 
The possibility that the unrearranged transgenes are not 
as "accessible" to the putative trans-acting factors required for 
hypermutation  as are functional H chain loci can not be directly 
evaluated due to the current lack of information regarding 
the nature of these factors. However,  a "suppressive"  effect 
of particular transgene integration sites seems unlikely since 
we have examined transgenes present in four independently 
derived transgenic lines of mice. Inactivation of the trans- 
genic loci for hypermutation due to sex-specific  parental "im- 
printing" (41) also seems unlikely since, as shown in Table 
1, the hybridomas we have examined were derived from first 
generation offspring obtained from both male and female 
founders (i.e., X7 and PR19 founders were females, and PR15 
and X1  founders were males).  Prdiminary analyses of the 
extent of cytosine methylation in the transgenic arrays indi- 
cate that these arrays are not hypermethylated. Finally, our 
Northern blot and RNase protection (Fig. 7) analyses show 
that the unrearranged transgenes can be transcribed in spleen, 
indicating accessibility  to the transcriptional machinery. 
Data obtained by us (15) and others (16) have shown that 
somatic mutation within a B call clone can occur after iso- 
type switching mediated by deletions within the C  region 
locus.  Thus,  a region required for hypermutation may be 
present 3' of this locus. The discovery of a second IgH en- 
hancer dement in this region (42) is intriguing in this re- 
gard, particularly in light of recent data suggesting that a 
region including the "downstream" enhancer dement in the 
mouse K locus is required for hypermutation of V~ trans- 
genes (25).  Finally, two MAR dements have been mapped 
to either side of the intronic IgH enhancer (43), and our largest 
transgenic constructs contain only a truncated form of the 
3' MAR element. Whether promoter activity,  enhancers, 
MAR regions, or other as yet undefined dements in IgH 
loci are requisite for V. somatic hypermutation should be 
directly testable  using the transgenic approach. 
naive spleen (Xl line); lane 6, spleen from an A/J mouse 3 d after a sec- 
ondary immunization with Ars-KLH, The RNA from hybridoma NX41-1 
does not protect the expected 243-base fragment, apparently due to the 
many nudeotide differences from the probe in its expressed H chain RNA 
resulting from somatic mutation. Autoradiographic exposures of lanes I-6 
and E-A  were for 7 and 1 d, respectively. We thank Kick Coffee, Vijaya Kommineni, Ethel Derr, and Alexander Krasev for technical assistance. 
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